Genomic signature of trastuzumab neoadjuvant therapy predictive of patient survival in HER2-positive breast cancer

被引：0
|
作者：
Briones, Natalia [1 ]
Facista, Salvatore [1 ]
Halperin, Rebecca [1 ]
Heaton, Paul [2 ]
Mahadevan, Daruka [3 ]
Hendricks, Wiiliam [1 ]
Kim, Suwon [2 ]
机构：
[1] Translat Genom Res Inst, Phoenix, AZ USA
[2] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA
[3] Univ Arizona, Ctr Canc, Tucson, AZ USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-3412
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3412
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [2] A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer
    Jia, Luyao
    Ling, Yuwei
    Li, Kaifu
    Zhang, Lina
    Wang, Yajun
    Kang, Hua
    CLINICAL BREAST CANCER, 2021, 21 (06) : E654 - E664
  • [3] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [4] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [6] Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
    Guiu, S.
    Reynier, M. A. Mouret
    Toure, M.
    Coudert, B.
    JOURNAL OF ONCOLOGY, 2013, 2013
  • [7] The predictive value of the mature B cell signature in early Her2-positive breast cancer treated with neoadjuvant therapy
    Lin, Po-Han
    Lo, Chiao
    Kuo, Sung-Hsin
    Huang, Chiun-Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [9] PD-1-Associated Gene Expression Signature of Neoadjuvant Trastuzumab-Treated Tumors Correlates with Patient Survival in HER2-Positive Breast Cancer
    Hendricks, William P. D.
    Briones, Natalia
    Halperin, Rebecca F.
    Facista, Salvatore
    Heaton, Paul R.
    Mahadevan, Daruka
    Kim, Suwon
    CANCERS, 2019, 11 (10)
  • [10] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
12345